| Subjects n | Imip/ merop | Pip/ tazo | CFP/ CFZ | CFX/ CRO | A/C A/S | Amino-glycosides | Quinolones | Glyco-protein | Linezolid | Colistin | Others | |
| Medical VAP | ||||||||||||
| Early onset | 206 | 15.5 | 13.6 | 3.9 | 10.7 | 9.7 | 8.3 | 10.2 | 9.7 | 3.4 | 0.5 | 14.5 |
| Late onset | 296 | 20.3 | 12.8 | 6.4 | 4.7 | 3 | 12.2 | 11.5 | 10.1 | 5.4 | 4.7 | 8.8 |
| Overall | 502 | 18.3 | 13.1 | 5.4 | 7.2 | 5.8 | 10.6 | 11.0 | 10.0 | 4.6 | 3.0 | 11.0 |
| Surgical VAP | ||||||||||||
| Early onset | 54 | 13.0 | 22.2 | 5.6 | 3.7 | 3.7 | 1.9 | 11.1 | 7.4 | 3.7 | 0 | 27.7 |
| Late onset | 96 | 13.5 | 16.7 | 6.3 | 4.2 | 3.1 | 3.1 | 12.5 | 15.6 | 9.4 | 1.0 | 14.5 |
| Overall | 150 | 13.3 | 18.7 | 6 | 4 | 3.3 | 2.7 | 12.0 | 12.7 | 7.3 | 0.7 | 19.3 |
| Trauma VAP | ||||||||||||
| Early onset | 107 | 18.7 | 13.1 | 4.7 | 17.8 | 5.6 | 8.4 | 5.6 | 7.5 | 0.9 | 2.8 | 14.9 |
| Late onset | 158 | 24.0 | 7.0 | 5.1 | 7.6 | 1.9 | 8.9 | 7.6 | 6.3 | 7.6 | 9.5 | 14.5 |
| Overall | 265 | 21.9 | 9.4 | 4.9 | 11.7 | 3.4 | 8.7 | 6.8 | 6.8 | 4.9 | 6.8 | 14.7 |
Data are presented as %, unless otherwise stated. Imip/merop: imipenem/meropenem; Pip/tazo: piperacillin-tazobactam; CFP/CFZ: cefepime/ceftazidime; CFX/CRO: cefotaxime/ceftriaxone; A/C: amoxicillin-clavulanate; A/S: ampicillin-sulbactam.